Valneva's Phase 2 data show strong, lasting immunity for its Pfizer-partnered Lyme vaccine as the company consolidates operations in France.

More than a year after its promised deadline to investors, drugmaker puts alarming results in federal government's "virtual ...

The top vaccine chief at the Food and Drug Administration sent out a memo saying the FDA will seek a stricter review and ...

NEW YORK, N.Y. – Pfizer Inc. on Monday released detailed analyses of myocarditis cases linked to its COVID-19 vaccine, ...

Investing.com -- Valneva SE stock rises after the company reported final positive Phase II data for its Lyme disease vaccine candidate VLA15, showing strong immune responses following a third annual ...

Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in ...

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease vaccine candidate, VLA15. The results showed ...

A recent study has provided the first side-by-side comparison of how three major COVID-19 vaccine types differ in triggering ...

The FDA’s top vaccine regulator asserted in a staff email that the Covid vaccine caused at least 10 kids' deaths, but experts ...

Shares of Moderna and BioNTech fell on Monday, likely in response to a FDA official's memo outlining a link between COVID-19 mRNA vaccines and myocarditis deaths in 10 children. Concern about that ...

COVID-19 risk might be much lower than in past summers, but it’s not gone - making a pre-Christmas booster for some a good idea.

Elders need to get shots this season to be protected against major viruses and other illnesses. There are many to choose from ...